Synergistic RNA Delivery Systems for Enhanced Immunization

This inventive concept integrates RNA delivery with distinct technologies like AI, IoT, blockchain, and new materials to create more powerful systems for immunization, enhancing immunogenicity and personalized treatment.

The original patent addressed the need for non-viral delivery of RNA for immunization, but it had limitations in terms of optimizing RNA sequences, monitoring immune responses, and ensuring the integrity of RNA replicons. This new concept solves these problems by synergistically combining RNA delivery with AI, IoT, blockchain, and new materials to create more effective and personalized immunization systems.

The inventive concept comprises a range of systems and methods that integrate RNA delivery with AI-powered RNA sequence optimization, IoT-enabled real-time immune response monitoring, blockchain-secured RNA replicons, and nanomaterial-based RNA carriers. For instance, one embodiment involves a liposome-based delivery vehicle integrated with an AI-powered RNA sequence optimization module to enhance immunogenicity. Another embodiment features a composition for RNA-based immunization that comprises a blockchain-secured RNA replicon encoding a protein of interest and a microRNA-based adjuvant for enhanced immune activation. These systems and methods can be tailored to specific diseases and patient populations, enabling personalized immunotherapy.

The new claims introduce a synergistic combination of RNA delivery with distinct technologies, which is not obvious from the original patent. The integration of AI, IoT, blockchain, and new materials with RNA delivery creates a new, more powerful system that enhances immunogenicity and personalized treatment, which is not anticipated by the original patent.

Alternative embodiments may include the use of different AI algorithms for RNA sequence optimization, various IoT sensors for real-time immune response monitoring, or alternative blockchain protocols for securing RNA replicons. Other variations may involve the use of different nanomaterials for RNA carriers or the integration of additional technologies like CRISPR-Cas9 gene editing.

This inventive concept has significant commercial potential in the fields of immunotherapy, vaccine development, and personalized medicine. The target market includes pharmaceutical companies, biotech firms, and research institutions focused on developing innovative immunization systems.